Literature DB >> 23339388

Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma.

Lina Wu1, Li Li, Shucong Meng, Ruizhao Qi, Zebin Mao, Ming Lin.   

Abstract

BACKGROUND AND AIM: Arginine is a nonessential amino acid for humans and mice because it can be synthesized from citrulline by argininosuccinate synthetase (ASS) and argininosuccinate lyase. Hepatocellular carcinoma (HCC) is believed to be auxotrophic for arginine through the lack of expression of ASS. However, there are also some ASS-positive HCC cells. Therefore, the aim of this article was to study the levels of arginine and the expression of ASS in patients with HCC.
METHODS: Thirty patients with HCC who had undergone HCC surgery were enrolled in the study. Serum arginine levels were determined with an automatic amino acid analyzer. ASS expression was examined by Western blot and immunohistochemistry. Methylation specific polymerase chain reaction and methylation sequencing were performed to detect the methylation of DNA encoding ASS.
RESULTS: There was a decrease of arginine in HCC patients compared with that of healthy control. High expression of ASS was found in the adjacent tissues by Western blot and immunohistochemistry. Little ASS expression was found in most HCC tissues, but there were also some HCC tissues that expressed low levels of ASS. Methylation of the DNA encoding ASS was obviously higher in HCC tissues than that in paired adjacent tissues.
CONCLUSIONS: ASS expression is decreased significantly in HCC tissues. The downregulation of arginine and ASS expression may be a self-defense action of the body against malignant tumors, and the decreased arginine and ASS levels in HCC patients are an advantage for the arginine deiminase treatment.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23339388     DOI: 10.1111/jgh.12043

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  17 in total

1.  Molecular modeling and LC-MS-based metabolomics of a glutamine-valproic acid (Gln-VPA) derivative on HeLa cells.

Authors:  M J Fragoso-Vázquez; D Méndez-Luna; M C Rosales-Hernández; G R Luna-Palencia; A Estrada-Pérez; Benedicte Fromager; I Vásquez-Moctezuma; J Correa-Basurto
Journal:  Mol Divers       Date:  2020-04-24       Impact factor: 2.943

2.  A reliable LC-MS/MS method for the quantification of natural amino acids in mouse plasma: Method validation and application to a study on amino acid dynamics during hepatocellular carcinoma progression.

Authors:  Zhenzhen Liu; Mei-Juan Tu; Chao Zhang; Joseph L Jilek; Qian-Yu Zhang; Ai-Ming Yu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-06-02       Impact factor: 3.205

3.  Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors.

Authors:  Rom Keshet; Joo Sang Lee; Lital Adler; Eytan Ruppin; Ayelet Erez; Muhammed Iraqi; Yarden Ariav; Lisha Qiu Jin Lim; Shaul Lerner; Shiran Rabinovich; Roni Oren; Rotem Katzir; Hila Weiss Tishler; Noa Stettner; Omer Goldman; Hadas Landesman; Sivan Galai; Yael Kuperman; Yuri Kuznetsov; Alexander Brandis; Tevi Mehlman; Sergey Malitsky; Maxim Itkin; S Eleonore Koehler; Yongmei Zhao; Keyur Talsania; Tsai-Wei Shen; Nir Peled; Igor Ulitsky; Angel Porgador
Journal:  Nat Cancer       Date:  2020-08-31

Review 4.  DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma.

Authors:  Sumadi Lukman Anwar; Ulrich Lehmann
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

5.  Expression profile and down-regulation of argininosuccinate synthetase in hepatocellular carcinoma in a transgenic mouse model.

Authors:  Shih-Chang Shiue; Miao-Zeng Huang; Ting-Fen Tsai; Alice Chien Chang; Kong Bung Choo; Chiu-Jung Huang; Tsung-Sheng Su
Journal:  J Biomed Sci       Date:  2015-01-23       Impact factor: 8.410

6.  The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.

Authors:  Angkana Thongkum; Chunjing Wu; Ying-Ying Li; Medhi Wangpaichitr; Panida Navasumrit; Varabhorn Parnlob; Thaniya Sricharunrat; Vajarabhongsa Bhudhisawasdi; Mathuros Ruchirawat; Niramol Savaraj
Journal:  Int J Mol Sci       Date:  2017-06-01       Impact factor: 5.923

Review 7.  The Diverse Functions of Non-Essential Amino Acids in Cancer.

Authors:  Bo-Hyun Choi; Jonathan L Coloff
Journal:  Cancers (Basel)       Date:  2019-05-15       Impact factor: 6.639

8.  BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.

Authors:  Ying-Ying Li; Chunjing Wu; Shu-Mei Chen; Sumedh S Shah; Medhi Wangpaichitr; Lynn G Feun; Macus T Kuo; Miguel Suarez; Jeffrey Prince; Niramol Savaraj
Journal:  Oncotarget       Date:  2016-04-05

9.  Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.

Authors:  Youngji Kim; Eisuke Kobayashi; Daisuke Kubota; Yoshiyuki Suehara; Kenta Mukaihara; Keisuke Akaike; Ayumu Ito; Kazuo Kaneko; Hirokazu Chuman; Akira Kawai; Shigehisa Kitano
Journal:  Oncotarget       Date:  2016-10-25

Review 10.  Arginine and the metabolic regulation of nitric oxide synthesis in cancer.

Authors:  Rom Keshet; Ayelet Erez
Journal:  Dis Model Mech       Date:  2018-08-06       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.